Antineoplastic Agents, Alkylating
"Antineoplastic Agents, Alkylating" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
MeSH Number(s)
D27.505.519.124.035
D27.505.954.248.150
D27.888.569.035.035
Concept/Terms
Antineoplastic Agents, Alkylating- Antineoplastic Agents, Alkylating
- Antineoplastic Alkylating Agents
- Alkylating Agents, Antineoplastic
- Antineoplastic Drugs, Alkylating
- Antineoplastics, Alkylating
- Alkylating Antineoplastic Drugs
- Alkylating Drugs, Antineoplastic
- Antineoplastic Alkylating Drugs
- Drugs, Antineoplastic Alkylating
- Alkylating Antineoplastic Agents
- Alkylating Antineoplastics
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Alkylating".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Alkylating".
This graph shows the total number of publications written about "Antineoplastic Agents, Alkylating" by people in Harvard Catalyst Profiles by year, and whether "Antineoplastic Agents, Alkylating" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 0 | 3 |
| 1996 | 4 | 3 | 7 |
| 1997 | 3 | 7 | 10 |
| 1998 | 4 | 3 | 7 |
| 1999 | 3 | 6 | 9 |
| 2000 | 4 | 3 | 7 |
| 2001 | 6 | 5 | 11 |
| 2002 | 9 | 2 | 11 |
| 2003 | 10 | 2 | 12 |
| 2004 | 7 | 3 | 10 |
| 2005 | 11 | 6 | 17 |
| 2006 | 9 | 4 | 13 |
| 2007 | 11 | 6 | 17 |
| 2008 | 6 | 5 | 11 |
| 2009 | 8 | 9 | 17 |
| 2010 | 8 | 5 | 13 |
| 2011 | 9 | 12 | 21 |
| 2012 | 8 | 5 | 13 |
| 2013 | 20 | 3 | 23 |
| 2014 | 12 | 7 | 19 |
| 2015 | 13 | 5 | 18 |
| 2016 | 9 | 10 | 19 |
| 2017 | 15 | 6 | 21 |
| 2018 | 7 | 7 | 14 |
| 2019 | 9 | 8 | 17 |
| 2020 | 11 | 6 | 17 |
| 2021 | 5 | 4 | 9 |
| 2022 | 0 | 8 | 8 |
| 2023 | 0 | 3 | 3 |
| 2024 | 0 | 1 | 1 |
Below are the most recent publications written about "Antineoplastic Agents, Alkylating" by people in Profiles.
-
dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma. J Neurooncol. 2024 Jan; 166(1):129-142.
-
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses. J Neurooncol. 2023 Sep; 164(3):607-616.
-
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study. Neuro Oncol. 2023 06 02; 25(6):1113-1122.
-
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro Oncol. 2023 01 05; 25(1):123-134.
-
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. J Clin Oncol. 2023 03 01; 41(7):1453-1465.
-
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 2022 11 02; 24(11):1935-1949.
-
Current therapeutic options for glioblastoma and future perspectives. Expert Opin Pharmacother. 2022 Oct; 23(14):1629-1640.
-
A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma. Clin Cancer Res. 2022 06 01; 28(11):2306-2312.
-
Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas. J Neurooncol. 2022 Jul; 158(3):341-348.
-
Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients. J Neurooncol. 2022 May; 158(1):111-116.